TY - JOUR T1 - 8R-Lisuride Is a Potent Stereospecific Histamine H<sub>1</sub>-Receptor Partial Agonist JF - Molecular Pharmacology JO - Mol Pharmacol SP - 538 LP - 549 DO - 10.1124/mol.65.3.538 VL - 65 IS - 3 AU - R. A. Bakker AU - D. M. Weiner AU - T. ter Laak AU - T. Beuming AU - O. P. Zuiderveld AU - M. Edelbroek AU - U. Hacksell AU - H. Timmerman AU - M. R. Brann AU - R. Leurs Y1 - 2004/03/01 UR - http://molpharm.aspetjournals.org/content/65/3/538.abstract N2 - The human histamine H1 receptor (H1R) is an important, well characterized target for the development of antagonists to treat allergic conditions. Many neuropsychiatric drugs are known to potently antagonize the H1R, thereby producing some of their side effects. In contrast, the tolerability and potential therapeutic utility of H1R agonism is currently unclear. We have used a cell-based functional assay to evaluate known therapeutics and reference drugs for H1R agonist activity. Our initial functional screen identified three ergot-based compounds possessing heretofore-unknown H1R agonist activity. 8R-lisuride demonstrated potent agonist activity in various assays including receptor selection and amplification technology, inositol phosphate accumulation, and activation of nuclear factor-κB with pEC50 values of 8.1, 7.9, and 7.9, respectively, and with varying degrees of efficacy. Based on these assays, 8R-lisuride is the most potent stereospecific partial agonist for the human H1R yet reported. Investigation of the residues involved in histamine and lisuride binding, using H1R mutants and molecular modeling, have revealed that although these ligands are structurally different, the lisuride-binding pocket in the H1R closely corresponds to the histamine-binding pocket. The discovery of a potent stereospecific partial H1R agonist provides a valuable tool to further characterize this important therapeutic target in vitro. ER -